Close Menu

GSK

While much attention has been focused on the use of microRNAs for diagnostic applications, a number of pharmaceutical firms have been exploring the non-coding RNAs' potential as biomarkers of drug-related toxicity.

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

In 2013, the top selling pharmacogenetically targeted drugs were well-known personalized medicine products, Herceptin and Gleevec.

NEW YORK (GenomeWeb News) – Response Genetics today said that it has received the third milestone payment from GlaxoSmithKline related to a licensing agreement reached by the two firms in March 2010.

Enigma Diagnostics said this week that it has received CE IVD marking for its Enigma ML system and first assay, a combined molecular test for influenza A/B and respiratory syncytial virus.

Originally published Jan. 14.

Originally published Dec. 12. SAN ANTONIO, TEX. – Fifteen years after it came on the market, Herceptin is still the poster child for personalized medicine, and when combined with chemotherapy it's still the standard of care for HER2-positive breast cancer.

Having validated the performance of its mass spec-based TIQUAS system for the identification of protein biomarkers in clinical samples, proteomics firm Activiomics is now aiming to step up its biomarker development efforts.

Originally published Aug. 13.
The combined sales from Roche's treatments for HER2-positive breast cancer took the lead for pharmacogenomically targeted cancer drugs during the second quarter.

Pages

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.